Stockscreener 앱 받기
0.7016
1.32%
-0.0094
시간 외 거래:
.74
0.0384
+5.47%
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Aprea reports partial response in APR-1051 cancer trial - MSN
Aprea Therapeutics, Inc.Common Stock (NQ: APRE - FinancialContent
Aprea Reports Partial Response in APR-1051 Cancer Trial - MyChesCo
Former Aprea CEO Christian Schade joins Frazier after Halda sale - Stock Titan
APRE PE Ratio & Valuation, Is APRE Overvalued - Intellectia AI
Stocks in play: CGI Inc. - Barchart.com
APRE SEC FilingsAprea Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Soleus entities and Guy Levy report 1.27M shares in Aprea (NASDAQ: APRE) - Stock Titan
Aprea Therapeutics (APRE) CFO buys pre-funded and common warrants - Stock Titan
Aprea Therapeutics (APRE) director buys pre-funded and common stock warrants - Stock Titan
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - bitget.com
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline - TipRanks
Weekly Earnings: Is Aprea Therapeutics Inc stock a buy or sell2026 Big Picture & Fast Gain Stock Tips - baoquankhu1.vn
Aprea Therapeutics closes $30 million private placement - Investing.com
Aprea Therapeutics closes $30 million private placement By Investing.com - Investing.com India
Aprea closes oversubscribed $30M private placement to fund APR-1051 clinical expansion - TradingView
Aprea Therapeutics (NASDAQ: APRE) closes $30M oversubscribed funding - Stock Titan
Aug Fed Impact: How does Aprea Therapeutics Inc perform in inflationary periods2026 Volume Leaders & AI Optimized Trade Strategies - baoquankhu1.vn
Aprea Therapeutics (NASDAQ:APRE) Given Outperform Rating at Wedbush - Defense World
Aprea reports 2025 results, early data for APR-1051 trial - MSN
Aprea Therapeutics Announces $30 Million Private Placement - The Globe and Mail
APRE: Wedbush Reiterates 'Outperform' Rating with $7 Target | AP - GuruFocus
Aprea reports confirmed tumor response in WEE1 inhibitor trial - Investing.com
Aprea reports confirmed tumor response in WEE1 inhibitor trial By Investing.com - Investing.com South Africa
Aprea Therapeutics raises $30 million in private placement By Investing.com - Investing.com Australia
Aprea Therapeutics (NASDAQ:APRE) versus Ocugen (NASDAQ:OCGN) Head-To-Head Comparison - Defense World
Aprea’s $30 million funding may lead to significant dilution with the 2028 deadline approaching - bitget.com
Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc - MarketScreener
Aprea Therapeutics (Nasdaq: APRE) secures $30M and reports WEE1 trial response - Stock Titan
Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investors - marketscreener.com
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial - bitget.com
Aprea Reports Confirmed Partial Response In APR-1051 Trial And Announced $30M Private Placement - RTTNews
Aprea Therapeutics raises $30 million in private placement - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Cancer drug developer raises $30M to fund lead trial into 2028 - Stock Titan
After a 50% drop, an endometrial tumor shrank again on APR-1051 - Stock Titan
EPS Watch: How cyclical is Aprea Therapeutics Incs revenue streamQuarterly Trade Report & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Risk Hedge: How cyclical is Aprea Therapeutics Incs revenue stream - baoquankhu1.vn
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update - Defense World
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen - MSN
Aprea to present at Oppenheimer Healthcare Conference - MSN
Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks - Barchart.com
Price Action: Is Aprea Therapeutics Inc affected by consumer sentimentMarket Movers & Daily Chart Pattern Signals - baoquankhu1.vn
Market Review: Is Aprea Therapeutics Inc a potential multi baggerRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Aprea Reports 2025 Results, Early Data for APR-1051 Trial - MyChesCo
Aprea Therapeutics advanced cancer trial shows promising results, stock soars - MSN
[EFFECT] Aprea Therapeutics, Inc. SEC Filing - Stock Titan
1.51%
1.75%
자본화:
|
볼륨(24시간):